KRAS and urinary bladder carcinoma: The association led to an enhanced anti-proliferative effect in mutant KRAS (Kirsten rat sarcoma viral oncogene homolog) lung cancer and melanoma cells [59], and in mutant-p53 bladder cancer cells [44].